Active immunotherapy with allogeneic tumor cell vaccines: present status.
This review will concentrate on allogeneic vaccines for melanoma The important principles of melanoma vaccine effectiveness are discussed in detail, followed by a review of the progress of several clinical trials investigating allogeneic vaccines. No therapeutic cancer vaccine has yet been approved for general use by the US Food and Drug Administration. However, much progress has been made in the field of vaccine immunotherapy, especially for the treatment of melanoma. Active immunotherapy with tumor vaccines is progressing rapidly as an emerging option for cancer therapy.
Chan
A D
AD
Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA.
Morton
D L
DL
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016233:Immunotherapy, Active; D008545:Melanoma / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines